Where IL-15 Stands in NK Cell Therapy: Three Routes and the Evidence Each Demands
From ex vivo NK expansion to IL-15 superagonist fusions and CAR-NK programs, IL-15 sits at the evidence gate of each route. This article traces the chain.
- Recent Advances
- Product Information
Recent Advances
Abstract: From ex vivo NK expansion to IL-15 superagonist fusions and CAR-NK programs, IL-15 sits at the evidence gate of each route. This article traces the chain.
Keywords: IL-15, NK cell therapy, CAR-NK, IL-15 superagonist, ex vivo expansion, UA040010
Note: The full article is published in Chinese. Please refer to the Chinese version for complete experimental details, figures and product references. For product inquiries, visit www.ua-bio.com.
Product Information






